On #EuropeanMyelomaDay, SYNTHIA highlights our Multiple Myeloma use case. Using synthetic data, we build external control arms for trials, assess MRD, and integrate genomics with imaging — to improve therapies and patient outcomes.
#SYNTHIA #SyntheticData #MyelomaResearch #IHITransformingHealth
Only 26 days until #IMS25 in Toronto!☁️✨The sky’s the limit for what we will achieve together. Join us for groundbreaking insights, collaboration and innovation. #MultipleMyeloma #MyelomaResearch ➡️ rb.gy/139j28
#MultipleMyeloma #CAR_T #Talquetamab #RRMM #Oncology #Hematology #CellTherapy #RealWorldEvidence #MyelomaResearch #Immunotherapy #GPRC5D #BCMA
The #IMS25 abstract deadline is just days away—submissions close this Friday at 11:59 PM EDT. 🔗 Submit now: rb.gy/cb8sgq #CallForAbstracts #MyelomaResearch
The myeloma community is talking, and they’re all heading to Toronto.✈️📍Join us at #IMS25 this September 17–20! ➡️ Register today: rb.gy/139j28 #MyelomaResearch #GlobalMyeloma
Attention young investigators! 🔬 There is still time to apply for the 5th Annual Career Development Award. 📝 Deadline is Jan 31 - learn more today. ow.ly/1tb850TXPuv #MyelomaResearch #YoungInvestigatorGrant
📢 Breaking news from #ASH24! Daratumumab vs. active monitoring in smoldering myeloma shows:
✅ Significantly delayed disease progression
✅ Improved survival
✅ Under FDA review for high-risk SMM
This could transform early myeloma treatment from "watch & wait" to active intervention! #MyelomaResearch
Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch
Hello, Bluesky! 👋 Thrilled to join this space. I’m an Asst Prof working at the intersection of #CancerGenomics and computational biology, with a focus on high-risk #MultipleMyeloma. Looking forward to connecting with researchers, clinicians, and anyone passionate about advancing #MyelomaResearch! 🧬✨
